Decision Making, SharedImPartNCT06173323
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
A study testing ImPart - Improving Chronic Kidney Disease Decisional Partnerships in people with Decision Making, Shared and Family Caregiving, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
- What is being tested?
- ImPart - Improving Chronic Kidney Disease Decisional Partnerships
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Sep 2024to 31 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients
- Age ≥18;
- EMR documented diagnosis of stage 4 CKD (2 eGFR 29-15 within 90 days);
- Ability to speak and read English and complete baseline questionnaires;
- Patients must have an enrolled caregiver
- Caregivers
Show all 11Show fewer
- Age ≥18;
- Self-endorsing or identified by the patient as a relative, friend, or partner that has a close relationship with you and who assists you with your medical decisions and who may or may not live in the same residence as you and who is not paid for their help
- Caring for a patient with CKD;
- Ability to speak and read English and complete baseline questionnaires;
- Caregivers must have an enrolled patient.
Who cannot join
- Patients
- Receiving hospice;
- Receiving dialysis;
- Medical record documentation of active unmedicated severe mental illness, moderate-severe dementia, suicidal ideation, uncorrected hearing loss, and active substance abuse.
- Caregivers 1) Self-reported unmedicated mental illness, Moderate-severe dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse ascertained by scripted study introduction questioning.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Shena Gazaway
Birmingham, Alabama, 35294-1150
Shena Gazaway, 2059755304, gazaways@uab.edu
About this study
Official title: An Optimization Trial of a Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Health Model of Family Caregiving and Rini's Social Support Effectiveness theory. The components include: 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no).
Read the detailed description
Of the estimated 37 million U.S. adults with chronic kidney disease (CKD), many who are newly diagnosed with advancing CKD rely on the support of family caregivers to help cope with serious illness and make health-related decisions, such as dialysis and end of life choices. Underprepared family and patient decision-makers may lack CKD knowledge, have poor disease understanding, and unclear expectations about treatments, especially at the end of life. Underprepared CKD dyads (patient and caregiver) may experience greater decisional conflict, ineffective coping, and heightened distress compared to adequately prepared ones. Black CKD patients and their families who face discrimination experience additional obstacles when navigating health-related decisions.
There is a critical need to train CKD dyads to effectively partner with each other and their clinicians when contemplating treatment related decisions, early in disease trajectory to increase trust and enhance communication. However, few interventions exist to enhance dyad skills in effectively requesting the specific support and resources they need to successfully navigate decision-making and to manage their illness experience. To date, systematic reviews and national reports have highlighted how interventions to optimize health-related decision-making in CKD have focused mainly on the patient and have not included the family caregiver, particularly in historically excluded populations. Furthermore, nearly all work has focused on interventions for specific CKD medical decisions and not the broader landscape of health-related decision-making along the CKD illness trajectory (i.e., biopsy, medication regiment, diet and nutrition). To develop an intervention to enhance the decision-making partnership between CKD dyads, the investigators have identified intervention components from other caregiving interventions that focus on optimizing the dyad's ability to partner in decision-making earlier in the course of illness. However, it is unknown which of these components and component combinations might best comprise a packaged intervention that optimizes patient and caregiver health-related decision-making as related to advancing CKD. Traditional intervention development approaches typically treat interventions as "bundled" treatment packages, making it difficult to determine which components of an intervention are effective. Hence, the investigators propose an intervention development and testing approach using the Multiphase Optimization Strategy (MOST), aiming to develop and test intervention components more efficiently.
Study Objective: The overall purpose of this study is to pilot test components of ImPart (Improving Chronic Kidney Disease Decisional Partnerships), a telehealth, decision support training intervention for stage 4 CKD dyads (2 estimated glomerular filtration rate [eGFR] values between 15ml/min - 29ml/min in the last 90 days based on the new 2021 CKD-EPI creatinine race-free equation), using pilot data from current works and the MOST framework for intervention development and testing. A pilot 2X2X2 factorial trial to assess the stakeholder-informed individual components to evaluate feasibility, acceptability, and preliminary component efficacy with 64 stage 4 CKD dyads (128 individuals) randomized to 1 of 8 experimental conditions. Tentative intervention components include 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no).
The research specific aims (SA) are to:
SA 1. Determine acceptability \& feasibility of the refined intervention components in a sample of 64 dyads over 24 weeks using a pilot factorial design. Feasibility: Completion of ≥75% of intervention session \&; data collection completion and the results of the feasibility of intervention measure. Acceptability: Post-intervention acceptability interviews, acceptability of intervention measure, and intervention appropriateness measure.
SA 2. Explore the preliminary efficacy of individual intervention components on patient and caregiver outcomes over 24 weeks, including patient-reported decisional conflict using the Decision Conflict Scale (primary). Secondary outcomes: Patients: a) social support effectiveness (Social Support Effectiveness Scale), b) distress (Hospital Anxiety and Depression Scale), c) quality of life (Kidney Disease Quality of Life 36-item short-form [KDQOL-36]) Caregivers: a) distress (Hospital Anxiety and Depression Scale), b) quality of life (PROMIS Global 10) Both: dyadic interaction (Dyadic Coping Inventory).
- Being tested
- ImPart - Improving Chronic Kidney Disease Decisional Partnerships
- Keywords
- chronic kidney disease, shared decision making, family caregiving
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ImPart - Improving Chronic Kidney Disease Decisional PartnershipsBehavioural
ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
| Study group | Role | What they receive |
|---|---|---|
| Basic social support + communication + patient psychoeducation | Experimental | 2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Basic social support + communication | Experimental | 2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Basic social support + patient psychoeducation | Experimental | 1 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Basic social support | Experimental | 1 in-person/telephone weekly sessions on providing social support for caregiver participants a single monthly follow-up call for the caregiver participant. Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Advanced social support + communication+ patient psychoeducation | Experimental | 4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Advanced social support + communication | Experimental | 4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Advanced social support + patient psychoeducation | Experimental | 3 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
| Advanced social support | Experimental | 3 in-person/telephone weekly sessions on providing social support for caregiver participants and a single monthly follow-up call for caregiver participant Receives: Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of Intervention Measure
four-item measure of implementation outcomes that are often considered "leading indicators" of implementation success; higher score indicate greater acceptability (highest score - 20)
Measured: 12 weeks
Intervention Appropriateness Measure
Four-item measure of implementation outcomes that are often considered "leading indicators" of implementation success; higher score indicate greater appropriateness (highest score - 20)
Measured: 12 weeks
Feasibility of Intervention
Intervention completion rate (# participants completing assigned components) will be tabulated, ≥75% completion rates for assigned components will be considered evidence of feasibility
Measured: 12 weeks after baseline
Feasibility of Data Collection
Intervention assessment completion rate (# participants completing each study assessment) will be tabulated, ≥75% completion rates for study assessments will be considered evidence of feasibility
Measured: baseline, 12 weeks, 24 weeks after baseline
Feasibility of Intervention Process
Feasibility of Intervention Measure a four-item measure of implementation - higher scores = greater feasibility (highest score - 20)
Measured: 12 weeks
Acceptability of Intervention and Study Procedures
Determined by thematic analysis, of digitally recorded, semi-structured qualitative interviews adapted from prior study teams' work. Open-ended questions will query participants about their experiences with their assigned intervention components, the navigator, study procedures, how program impacted their engagement in shared decision-making and changes they would like to see made to the intervention and study procedures.
Measured: 24 weeks
Secondary outcomes (6)
Health-related decision process for patient as measured by the Decision Conflict Scale
16-item measure; perceptions of uncertainty in choosing options, factors contributing to uncertainty (e.g., feeling uninformed, unclear values) and feeling that decisions were informed and values-based - Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].
Measured: baseline, 12 weeks, and 24 weeks after baseline
Health-related decision process for patient as measured by the Social Support Effectiveness- Questionnaire
25 item measure; perceptions of help received in last 3 months with higher scores indicating more effective support - The total possible score is 66 points
Measured: baseline, 12 weeks, and 24 weeks after baseline
Patient and Caregiver well-being/distress as measured by the Hospital Anxiety and Depression Scale
14 items total, items measure anxiety and depressive symptoms. Higher scores=worse anxiety/depression - Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Measured: baseline, 12 weeks, and 24 weeks after baseline
Patient wellbeing/quality of life as measured by the Kidney Disease Quality of Life Scale (KDQOL 36)
36 items measure three components: physical health score, mental health score, and kidney disease health score. Physical health score, mental health score, and kidney disease health score are averaged scores of sub-scales. The range of each score and each sub-scale is 0 - 100, and higher values indicate better QOL status
Measured: baseline, 12 weeks, and 24 weeks after baseline
Patient and caregiver interaction as measured by the Dyadic Coping Inventory
37-item instrument designed to measure perceived communication and dyadic coping in close relationships when one or both partners are stressed - higher scores = better coping between members of the dyad
Measured: baseline, 12 weeks, and 24 weeks after baseline
Caregiver wellbeing/quality of life as measured by the PROMIS Global Health 10
10 items, measures global health-related quality of life (HRQOL) in 2 domains: physical and mental health; scoring allows for cost-effectiveness estimates. Higher scores=higher HRQO
Measured: baseline, 12 weeks, and 24 weeks after baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2023
- Study start16 Sep 2024
- Primary completion31 Mar 2028 (estimated)
- Study completion31 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Decision Making, SharedStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shena Gazaway, University of Alabama at Birmingham
- Investigators
- Shena Gazaway, PhD, Principal investigator, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06173323
- Sponsor's protocol ID
- 300012221
- Other IDs
- 1K23DK134756
- Acronym
- ImPart
- Status last verified
- Dec 2025
- First submitted
- 7 Dec 2023
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gazaway S, Wells R, Gutierrez OM, Azuero A, Cole A, Nix-Parker T, Pitts L, Lyas C, Lang-Lindsey K, Knight R, Pazant P, Gustafuson N, Rayburn A, Umeukeje E, Odom JN. Decision support training for chronic kidney disease dyads: the ImPart Study protocol. Pilot Feasibility Stud. 2025 Dec 26;12(1):14. doi: 10.1186/s40814-025-01749-8.
PubMed 41449447
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Optimization Trial of a Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
- ClinicalTrials.gov ID
- NCT06173323
- Acronym / sponsor ID
- ImPart / 300012221
- Keywords
- chronic kidney disease, shared decision making, family caregiving
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 16 Sep 2024 (actual)
- Primary completion
- 31 Mar 2028 (estimated)
- Study completion
- 31 Mar 2028 (estimated)
- First posted
- 15 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Health Model of Family Caregiving and Rini's Social Support Effectiveness theory. The components include: 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no).
Detailed description
Of the estimated 37 million U.S. adults with chronic kidney disease (CKD), many who are newly diagnosed with advancing CKD rely on the support of family caregivers to help cope with serious illness and make health-related decisions, such as dialysis and end of life choices. Underprepared family and patient decision-makers may lack CKD knowledge, have poor disease understanding, and unclear expectations about treatments, especially at the end of life. Underprepared CKD dyads (patient and caregiver) may experience greater decisional conflict, ineffective coping, and heightened distress compared to adequately prepared ones. Black CKD patients and their families who face discrimination experience additional obstacles when navigating health-related decisions.
There is a critical need to train CKD dyads to effectively partner with each other and their clinicians when contemplating treatment related decisions, early in disease trajectory to increase trust and enhance communication. However, few interventions exist to enhance dyad skills in effectively requesting the specific support and resources they need to successfully navigate decision-making and to manage their illness experience. To date, systematic reviews and national reports have highlighted how interventions to optimize health-related decision-making in CKD have focused mainly on the patient and have not included the family caregiver, particularly in historically excluded populations. Furthermore, nearly all work has focused on interventions for specific CKD medical decisions and not the broader landscape of health-related decision-making along the CKD illness trajectory (i.e., biopsy, medication regiment, diet and nutrition). To develop an intervention to enhance the decision-making partnership between CKD dyads, the investigators have identified intervention components from other caregiving interventions that focus on optimizing the dyad's ability to partner in decision-making earlier in the course of illness. However, it is unknown which of these components and component combinations might best comprise a packaged intervention that optimizes patient and caregiver health-related decision-making as related to advancing CKD. Traditional intervention development approaches typically treat interventions as "bundled" treatment packages, making it difficult to determine which components of an intervention are effective. Hence, the investigators propose an intervention development and testing approach using the Multiphase Optimization Strategy (MOST), aiming to develop and test intervention components more efficiently.
Study Objective: The overall purpose of this study is to pilot test components of ImPart (Improving Chronic Kidney Disease Decisional Partnerships), a telehealth, decision support training intervention for stage 4 CKD dyads (2 estimated glomerular filtration rate [eGFR] values between 15ml/min - 29ml/min in the last 90 days based on the new 2021 CKD-EPI creatinine race-free equation), using pilot data from current works and the MOST framework for intervention development and testing. A pilot 2X2X2 factorial trial to assess the stakeholder-informed individual components to evaluate feasibility, acceptability, and preliminary component efficacy with 64 stage 4 CKD dyads (128 individuals) randomized to 1 of 8 experimental conditions. Tentative intervention components include 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no).
The research specific aims (SA) are to:
SA 1. Determine acceptability \& feasibility of the refined intervention components in a sample of 64 dyads over 24 weeks using a pilot factorial design. Feasibility: Completion of ≥75% of intervention session \&; data collection completion and the results of the feasibility of intervention measure. Acceptability: Post-intervention acceptability interviews, acceptability of intervention measure, and intervention appropriateness measure.
SA 2. Explore the preliminary efficacy of individual intervention components on patient and caregiver outcomes over 24 weeks, including patient-reported decisional conflict using the Decision Conflict Scale (primary). Secondary outcomes: Patients: a) social support effectiveness (Social Support Effectiveness Scale), b) distress (Hospital Anxiety and Depression Scale), c) quality of life (Kidney Disease Quality of Life 36-item short-form [KDQOL-36]) Caregivers: a) distress (Hospital Anxiety and Depression Scale), b) quality of life (PROMIS Global 10) Both: dyadic interaction (Dyadic Coping Inventory).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Basic social support + communication + patient psychoeducation | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. |
| Basic social support + communication | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant |
| Basic social support + patient psychoeducation | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships1 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. |
| Basic social support | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships1 in-person/telephone weekly sessions on providing social support for caregiver participants a single monthly follow-up call for the caregiver participant. |
| Advanced social support + communication+ patient psychoeducation | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. |
| Advanced social support + communication | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant |
| Advanced social support + patient psychoeducation | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships3 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants. |
| Advanced social support | Experimental | Behavioral: ImPart - Improving Chronic Kidney Disease Decisional Partnerships3 in-person/telephone weekly sessions on providing social support for caregiver participants and a single monthly follow-up call for caregiver participant |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patients
- Caregivers
Key exclusion criteria (5 listed)
- Patients
- Caregivers 1) Self-reported unmedicated mental illness, Moderate-severe dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse ascertained by scripted study introduction questioning.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ImPart - Improving Chronic Kidney Disease Decisional PartnershipsImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience. | Behavioural | Advanced social support, Advanced social support + communication, Advanced social support + communication+ patient psychoeducation, Advanced social support + patient psychoeducation, Basic social support, Basic social support + communication, Basic social support + communication + patient psychoeducation, Basic social support + patient psychoeducation |
Primary outcome
Acceptability of Intervention Measure
Time frame: 12 weeks
four-item measure of implementation outcomes that are often considered "leading indicators" of implementation success; higher score indicate greater acceptability (highest score - 20)
Intervention Appropriateness Measure
Time frame: 12 weeks
Four-item measure of implementation outcomes that are often considered "leading indicators" of implementation success; higher score indicate greater appropriateness (highest score - 20)
Feasibility of Intervention
Time frame: 12 weeks after baseline
Intervention completion rate (# participants completing assigned components) will be tabulated, ≥75% completion rates for assigned components will be considered evidence of feasibility
Feasibility of Data Collection
Time frame: baseline, 12 weeks, 24 weeks after baseline
Intervention assessment completion rate (# participants completing each study assessment) will be tabulated, ≥75% completion rates for study assessments will be considered evidence of feasibility
Feasibility of Intervention Process
Time frame: 12 weeks
Feasibility of Intervention Measure a four-item measure of implementation - higher scores = greater feasibility (highest score - 20)
Acceptability of Intervention and Study Procedures
Time frame: 24 weeks
Determined by thematic analysis, of digitally recorded, semi-structured qualitative interviews adapted from prior study teams' work. Open-ended questions will query participants about their experiences with their assigned intervention components, the navigator, study procedures, how program impacted their engagement in shared decision-making and changes they would like to see made to the intervention and study procedures.
6 secondary outcomes
Health-related decision process for patient as measured by the Decision Conflict Scale
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Health-related decision process for patient as measured by the Social Support Effectiveness- Questionnaire
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Patient and Caregiver well-being/distress as measured by the Hospital Anxiety and Depression Scale
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Patient wellbeing/quality of life as measured by the Kidney Disease Quality of Life Scale (KDQOL 36)
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Patient and caregiver interaction as measured by the Dyadic Coping Inventory
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Caregiver wellbeing/quality of life as measured by the PROMIS Global Health 10
Time frame: baseline, 12 weeks, and 24 weeks after baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Derived from this study: PubMed 41449447Gazaway S, Wells R, Gutierrez OM, Azuero A, Cole A, Nix-Parker T, Pitts L, Lyas C, Lang-Lindsey K, Knight R, Pazant P, Gustafuson N, Rayburn A, Umeukeje E, Odom JN. Decision support training for chronic kidney disease dyads: the ImPart Study protocol. Pilot Feasibility Stud. 2025 Dec 26;12(1):14. doi: 10.1186/s40814-025-01749-8.
- Individual participant dataSharing planned: No
Related trials for Decision Making, Shared
Recruiting
Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings.
Shared Decision Making
Recruiting
Evaluating a Digital Aid to Improve ICD Decisions
Shared Decision-making
Not yet recruiting
Team-Based Shared Decision-Making Program in Hypertension Control (Healthy Heart - BP Program)
Hypertension (HTN), Blood Pressure
Not yet recruiting
A Decision Support Tool for Common Surgical Fixations of Hip Fractures
Hip Fracture Surgeries, High Risk Population of Hip Fractures
Recruiting
Designing a Large Language Model Architecture for Shared Decision Making and Informed Intentions
Shared Decision Making, Health Literacy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shena Gazaway, PhD principal investigator
University of Alabama at Birmingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ImPart - Improving Chronic Kidney Disease Decisional Partnerships in people with Decision Making, Shared and Family Caregiving, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shena Gazaway, Phd, RN (205-975-5704, gazaways@uab.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability of Intervention Measure (time frame: 12 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06173323, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.